XML 45 R24.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. Segment net sales and segment operating income are based on internally derived foreign exchange rates and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. There were no customers that represented 10% or more of the Company's total net sales.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate research and development expenses, manufacturing variances, corporate headquarters costs, net interest income, global marketing expenses, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Segment Net Sales    
United States$804.6 $735.9 $2,393.1 $2,203.6 
Europe315.1 282.7 968.4 878.0 
Japan85.8 84.9 265.6 251.5 
Rest of World153.2 136.1 440.9 399.0 
Total segment net sales$1,358.7 $1,239.6 $4,068.0 $3,732.1 
Segment Operating Income    
United States$551.2 $498.4 $1,619.2 $1,510.2 
Europe177.3 156.1 540.3 489.2 
Japan54.4 53.7 159.8 158.5 
Rest of World67.2 59.5 184.7 170.6 
Total segment operating income$850.1 $767.7 $2,504.0 $2,328.5 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Net Sales Reconciliation    
Segment net sales$1,358.7 $1,239.6 $4,068.0 $3,732.1 
Foreign currency(4.3)3.8 (14.3)11.5 
Consolidated net sales$1,354.4 $1,243.4 $4,053.7 $3,743.6 
Pre-tax Income Reconciliation    
Segment operating income$850.1 $767.7 $2,504.0 $2,328.5 
Unallocated amounts:    
Corporate items(468.7)(410.1)(1,396.5)(1,259.4)
Restructuring expenses (Note 4)(32.9)— (32.9)— 
Intellectual property agreement and certain litigation expenses
(10.8)(2.2)(27.8)(193.6)
Change in fair value of contingent consideration liabilities— — — 26.2 
Foreign currency12.9 10.5 19.3 60.4 
Consolidated operating income350.6 365.9 1,066.1 962.1 
Non-operating income52.2 21.7 91.9 43.1 
Consolidated pre-tax income$402.8 $387.6 $1,158.0 $1,005.2 

Enterprise-wide Information
(in millions)

The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2024202320242023
Net Sales by Geographic Region    
United States$804.6 $735.9 $2,393.1 $2,203.6 
Europe319.8 286.5 978.0 877.7 
Japan81.4 85.8 253.9 266.4 
Rest of World148.6 135.2 428.7 395.9 
$1,354.4 $1,243.4 $4,053.7 $3,743.6 
Net Sales by Major Product Group    
Transcatheter Aortic Valve Replacement$1,023.3 $960.9 $3,069.8 $2,900.4 
Transcatheter Mitral and Tricuspid Therapies91.1 52.4 247.0 141.6 
Surgical Structural Heart240.0 230.1 736.9 701.6 
$1,354.4 $1,243.4 $4,053.7 $3,743.6